Wednesday - May 14, 2025
GREENFIELD, Ind., Feb. 20, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the launch of Pet Protect, a line of veterinarian-formulated supplements for dogs and cats. With the pet supplement market experiencing rapid growth and increasing relevance, Pet Protect emerges as a modernized, science-backed supplement line specifically designed to cater to the diverse health needs of pets.
As pet owners increasingly recognize the importance of their pets' health and well-being, their expectations for comprehensive pet care have risen significantly, resulting in a heightened awareness to take proactive measures to ensure not only their health but their pet's health too. The U.S. pet supplement market reached a size of $2.7 billion in 2023, achieving a Compound Annual Growth Rate (CAGR) of 20% over the past five years.1 The explosive growth in the pet supplements market has remained constant as customers see value in supplements – with over half of pet supplement purchasers reporting about the same spend in 2023 despite inflation price pressures.2 In response to this growing demand and the shifting focus of pet parents toward proactive wellness, Elanco has introduced Pet Protect to provide comprehensive support for pets' everyday health.
"As the leader in pet health over the counter products, expanding into supplements is a natural fit for Elanco," said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "This underscores our dedication to enhancing the health and well-being of pets while driving growth and expanding our footprint in this dynamic market."
Pet Protect stands out in the supplement market thanks to several distinct qualities:
"At Elanco, we recognize that pets are cherished family members and deserve the highest quality of care," said Dr. David Gosche, veterinarian and Executive Director, Consulting Vet Team at Elanco. "Pet Protect is designed to support the health of pets with scientifically formulated veterinarian-approved ingredients."
Pet Protect offers a full line of supplements, each with a unique function to improve the quality of life for pets. From promoting healthy skin, helping to support situational stress, supporting joint health and immune function, Pet Protect offers comprehensive solutions that meet the diverse needs of pets. The product line includes but is not limited to:
This launch reinforces Elanco's commitment to making life better for animals through innovative solutions that address a multitude of health needs for pets. For more information on Pet Protect, visit Pet Protect from the makers of Advantage.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Pet Protect, Advantage, Alenza, DVM Daily Soft Chews, Endurosyn, Free Form, Lactoquil, Seasoderm, Synovi G3, Synovi G4, Tranquilify, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. ®2025 Elanco or its affiliates.
1 Packaged Facts Pet Supplements in the US, 10th Edition, September 2024
2 Packaged Facts Pet Supplements in the US, 9th Edition, March 2023
Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Season Solorio, (765) 316-0233, season.solorio@elancoah.com
Last Trade: | US$13.02 |
Daily Change: | 0.20 1.56 |
Daily Volume: | 7,750,767 |
Market Cap: | US$6.440B |
February 25, 2025 February 25, 2025 November 15, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load